The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.

[1]  J. Sullivan,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide , 1997, European Journal of Clinical Pharmacology.

[2]  R. Fogari,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril , 1996, Journal of hypertension.

[3]  R. Fogari,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine , 1996, Clinical pharmacology and therapeutics.

[4]  S. Oparil.  Antihypertensive therapy in the era of evidence based medical practice: what to do until the facts are in. , 1996, Current opinion in nephrology and hypertension.

[5]  C. Johnston,et al.  Angiotensin receptor antagonists: focus on losartan , 1995, The Lancet.

[6]  I. Tikkanen,et al.  Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension , 1995, Journal of hypertension.

[7]  M. Haugh,et al.  A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice , 1995, Journal of Hypertension.

[8]  J. Bauer,et al.  The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. , 1995, Archives of internal medicine.

[9]  P Whelton,et al.  Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. , 1995, Hypertension.

[10]  A E Fletcher,et al.  Cough with angiotensin converting enzyme inhibitors: how much of a problem? , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[11]  S. Whitebread,et al.  Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype , 1993, British journal of pharmacology.

[12]  J. Ménard,et al.  IX - 1993 Guidelines for management of mild hypertension. Memorandum from a WHO/ISH meeting , 1993 .

[13]  H. Black,et al.  Current concepts refractory hypertension , 1992 .

[14]  A. Morice,et al.  Cough Associated with Angiotensin Converting Enzyme Inhibition , 1989, Journal of cardiovascular pharmacology.

[15]  Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension. , 1987, Journal of clinical hypertension.

[16]  L. Wilkins.  Management of patient compliance in the treatment of hypertension. Report of the NHLBI Working Group. , 1982, Hypertension.

[17]  M. Houston,et al.  Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. , 1981, American heart journal.

[18]  D. Sackett,et al.  RANDOMISED CLINICAL TRIAL OF STRATEGIES FOR IMPROVING MEDICATION COMPLIANCE IN PRIMARY HYPERTENSION , 1975, The Lancet.

[19]  Cole Pv.  Treatment of Reflux Oesophagitis , 1964 .